PL3731873T3 - Sposób dostarczania kompozycji pegylowanego białka - Google Patents

Sposób dostarczania kompozycji pegylowanego białka

Info

Publication number
PL3731873T3
PL3731873T3 PL18830893T PL18830893T PL3731873T3 PL 3731873 T3 PL3731873 T3 PL 3731873T3 PL 18830893 T PL18830893 T PL 18830893T PL 18830893 T PL18830893 T PL 18830893T PL 3731873 T3 PL3731873 T3 PL 3731873T3
Authority
PL
Poland
Prior art keywords
protein composition
pegylated protein
providing
providing pegylated
composition
Prior art date
Application number
PL18830893T
Other languages
English (en)
Inventor
Wolfgang Koehnlein
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL3731873T3 publication Critical patent/PL3731873T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL18830893T 2017-12-29 2018-12-28 Sposób dostarczania kompozycji pegylowanego białka PL3731873T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17211122 2017-12-29
EP18830893.6A EP3731873B1 (en) 2017-12-29 2018-12-28 Process for providing pegylated protein composition
PCT/EP2018/097125 WO2019129878A1 (en) 2017-12-29 2018-12-28 Process for providing pegylated protein composition

Publications (1)

Publication Number Publication Date
PL3731873T3 true PL3731873T3 (pl) 2022-04-25

Family

ID=60856965

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18830893T PL3731873T3 (pl) 2017-12-29 2018-12-28 Sposób dostarczania kompozycji pegylowanego białka

Country Status (11)

Country Link
US (1) US20200362002A1 (pl)
EP (1) EP3731873B1 (pl)
JP (2) JP7227633B2 (pl)
KR (1) KR102497097B1 (pl)
CN (1) CN111727063A (pl)
ES (1) ES2909454T3 (pl)
HR (1) HRP20220388T1 (pl)
PL (1) PL3731873T3 (pl)
SG (1) SG11202005952TA (pl)
SI (1) SI3731873T1 (pl)
WO (1) WO2019129878A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12208142B2 (en) * 2017-12-29 2025-01-28 Hoffmann-La Roche Inc. Process for providing PEGylated protein composition

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
SG88714A1 (en) 1989-11-06 2002-05-21 Cell Genesys Inc Production of proteins using homologous recombination
DE779362T1 (de) 1989-12-22 2001-04-05 Applied Research Systems Ars Holding N.V., Curacao DNS-Konstrukten zur Aktivierung und Veränderung der Expression von endogenen Genen
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
DE69332377T2 (de) 1992-07-13 2003-07-03 Bionebraska, Inc. Verfahren zur modifizierung rekombinanter polypeptide
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
WO2000044785A1 (en) 1999-01-29 2000-08-03 F. Hoffmann-La Roche Ag Gcsf conjugates
PE20010288A1 (es) * 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
MEP90708A (hr) * 2000-05-15 2011-12-20 Nova farmaceutska smješa
WO2004056852A2 (en) * 2002-12-19 2004-07-08 Nektar Therapeutics Al, Corp. Cyanovirin variant-polymer conjugates
AU2005278903A1 (en) * 2004-08-31 2006-03-09 Pharmacia & Upjohn Company Llc Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
WO2007010552A2 (en) * 2005-03-17 2007-01-25 Serum Institute Of India Limited N- terminal peg conjugate of erythropoietin
US8969532B2 (en) * 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
AR067537A1 (es) * 2007-07-17 2009-10-14 Hoffmann La Roche Purificacion de polipeptidos pegilados
CN107383158A (zh) * 2009-11-24 2017-11-24 诺沃—诺迪斯克保健股份有限公司 纯化聚乙二醇化蛋白质的方法
JP2013519652A (ja) * 2010-02-12 2013-05-30 ディーエスエム アイピー アセッツ ビー.ブイ. 単一ユニット抗体精製
CN102234310B (zh) * 2010-04-30 2017-02-08 杭州九源基因工程有限公司 一种聚乙二醇修饰蛋白的分离纯化方法
ES2500048T3 (es) * 2010-09-14 2014-09-29 F. Hoffmann-La Roche Ag Procedimiento para purificar eritropoyetina pegilada
CN102453087B (zh) * 2010-10-22 2013-12-25 广东赛保尔生物医药技术有限公司 一种单取代peg-epo的纯化及制备方法
CN111801120A (zh) * 2017-12-29 2020-10-20 豪夫迈·罗氏有限公司 用于提供聚乙二醇化蛋白质组合物的方法
US12208142B2 (en) * 2017-12-29 2025-01-28 Hoffmann-La Roche Inc. Process for providing PEGylated protein composition

Also Published As

Publication number Publication date
JP2021508706A (ja) 2021-03-11
SG11202005952TA (en) 2020-07-29
KR102497097B1 (ko) 2023-02-06
EP3731873B1 (en) 2022-01-26
EP3731873A1 (en) 2020-11-04
KR20200104382A (ko) 2020-09-03
SI3731873T1 (sl) 2022-05-31
JP7227633B2 (ja) 2023-02-22
HRP20220388T1 (hr) 2022-05-27
ES2909454T3 (es) 2022-05-06
JP2023055876A (ja) 2023-04-18
CN111727063A (zh) 2020-09-29
WO2019129878A1 (en) 2019-07-04
US20200362002A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
IL288613A (en) Multispecific proteins
ZA201705960B (en) Proteins specific for cd137
DK3445788T3 (en) Novel bispecific polypeptides against cd137
ZA201704231B (en) Chimeric protein
ZA201708041B (en) Novel proteins specific for lag-3
GB201502305D0 (en) Protein
GB201502306D0 (en) Protein
SG11202006140TA (en) Process for providing pegylated protein composition
SG11201704010UA (en) Fibroin-derived protein composition
DK3737402T3 (en) Modificeret protein
GB201905369D0 (en) Process
GB201608197D0 (en) Novel proteins
GB201711481D0 (en) Protein purification
GB201506223D0 (en) Chimeric protein
GB201515745D0 (en) Proteins
GB201511787D0 (en) Proteins
IL258570A (en) Stable protein preparations
PT3806660T (pt) Barra proteica
GB2558968B (en) G Proteins
ZA201901862B (en) Modified factor h binding protein
GB201600512D0 (en) Recombinant protein production
GB201513033D0 (en) Proteins
ZA202003722B (en) Modified globin proteins
SG11202005990RA (en) Process for providing pegylated protein composition
GB201704006D0 (en) Modified globin proteins